Trial reportLeukemia2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Trial report in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
152 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.
- Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.Frontiers in oncology · 2021Pooled it
- Trial
- Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.Haematologica · 2022Trial
- A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.Leukemia · 2022Trial
- Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.Blood advances · 2019Trial
- Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.Haematologica · 2018Trial
- Trial
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.Leukemia · 2018Trial
- Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.Leukemia · 2018Trial
- Trial
- Trial
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.Haematologica · 2017Trial
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.Cancer · 2017Trial
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.The New England journal of medicine · 2017Trial
- Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Leukemia · 2016Trial
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Leukemia · 2016Trial
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Leukemia · 2015Trial
- [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Trial
- Trial
- Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network.International journal of cancer · 2026Article
92 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have gained interest. The randomized CML - Study IV was used for a long-term evaluation of imatinib (IM). 1503 patients have received IM, 1379 IM monotherapy. After a median observation of 7.1 years, 965 patients (64%) still received IM. At 10 years, progression-free survival was 82%, overall survival 84%, 59% achieved MR(5), 72% MR(4.5), 81% MR(4), 89% major molecular remission and 92% MR(2) (molecular equivalent to complete cytogenetic remission). All response levels were reached faster with IM800 mg except MR(5). Eight-year probabilities of adverse drug reactions (ADR) were 76%, of grades 3-4 22%, of non-hematologic 73%, and of hematologic 28%. More ADR were observed with IM800 mg and IM400 mg plus interferon α (IFN). Most patients had their first ADR early with decreasing frequency later on. No new late toxicity was observed. ADR to IM are frequent, but mostly mild and manageable, also with IM 800 mg and IM 400 mg+IFN. The deep molecular response rates indicate that most patients are candidates for IM discontinuation. After 10 years, IM continues to be an excellent initial choice for most patients with CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.